- CA$75.53m
- CA$50.04m
Brief: Willow Biosciences Announces Ground-Breaking Scientific Data For Cannabigerol On Human Skin
Canada Research Roundup: Automotive Properties REIT, Boyd Group Services, George Weston
Brief: Willow Biosciences Reports Fourth Quarter And 2020 Year End Results And Operational Update
Brief: Willow Biosciences Announces $20.0 Million Bought Deal Offering
Brief: Willow Biosciences Announces Increase To Bought Deal Offering From $20.0 Million To $25.0 Million
Brief: Willow Biosciences Inc - Provides Update On Cannabigerol Research Studies And Key Personnel Appointment
Brief: Willow Biosciences Advances Commericalization Plan, First Commercial Production Expected In Early 2021
Brief: Willow Biosciences Anticipates Transitioning Into A Revenue Generating Development Company In 2021
Brief: Willow Biosciences Reports Exercise Of Over-Allotment Option
Brief: Willow Biosciences Announces Pricing And Upsize Of Previously Announced Public Offering To $10 Million
Brief: Willow Biosciences Announces Research And Development Funding For Its Varin Cannabinoids
Brief: Willow Reports First Quarter 2020 Results
Canada Research Roundup: AG Growth International, Mav Beauty Brands, Willow Biosciences
Brief: Willow Biosciences Inc - Appointed Dr. Peter Seufer-Wasserthal As Independent Chairman Of Board
Brief: Willow Biosciences Comments On Descheduling Of Partner's Cannabidiol By U.S. Drug Enforcement Agency
Brief: Willow Biosciences Receives Conditional Approval To List On Toronto Stock Exchange